Drug Discovery & Development Modalities
ChemPartner partners with biotech and pharma across two integrated pillars — Small Molecules (discovery, DMPK & safety, full CMC, and new chemical modalities) and Biologics & Advanced Biologics (antibodies, ADC/RDC, bispecifics, peptides, RNA, gene and cell therapy). One partner. Two decades of sponsor-grade delivery. 2,000+ scientists. A flexible engagement model built around your pipeline.
Experience and scale to move programs forward
For more than two decades, ChemPartner has combined scientific depth, integrated capabilities, and global scale to help partners advance discovery and development programs with confidence.
Discovery & development
Scientists worldwide
Drugs advanced to clinic
GMP biologics capacity
Two pillars, one partner
From AI-driven design to commercial API and finished dosage form — discovery chemistry, DMPK and safety, full CMC, and new chemical modalities under one project team.
From DNA to BLA-ready commercial supply — antibodies and the most demanding advanced modalities, integrated across discovery, engineering, and CDMO manufacturing.
Small Molecules
From AI-driven design to commercial API and finished dosage form — discovery chemistry, DMPK and safety, full CMC, and new chemical modalities under one project team.
Biologics & Advanced Biologics
From DNA to BLA-ready commercial supply — antibodies and the most demanding advanced modalities, integrated across discovery, engineering, and CDMO manufacturing.
Frequently asked questions
How are ChemPartner's modalities organized?
Across two pillars. Small Molecules covers discovery chemistry, DMPK/safety/biology, full CMC (API and formulation, process development to commercial supply), and new chemical modalities (PROTAC, protein degraders, molecular glue). Biologics & Advanced Biologics covers monoclonal antibodies, ADC/RDC, bispecifics, peptides and PDCs, RNA therapeutics, gene therapy, and cell therapies.
Does ChemPartner support small molecule CMC through to commercial manufacturing?
Yes — API R&D and manufacturing, formulation development, solid-state R&D, analytical development, process development, pilot scale-up and tech transfer, commercial manufacturing, and a full QMS, supporting IND, 505(b)(2), ANDA, and NDA pathways with IND-enabling packages in as little as ten months.
Does ChemPartner offer integrated programs across modalities?
Yes. Medicinal chemistry, biologics, biology, in vivo pharmacology, DMPK, and toxicology under one project team — ideal for combination strategies such as ADCs, BsADCs, AOCs, PDCs, and degrader-conjugates.
What engagement models does ChemPartner offer?
FTE, FFS, blended teams, and risk-share / milestone-based partnerships, with flexibility to scale teams up or down.
Where are ChemPartner's facilities located?
Six major sites — Shanghai Zhangjiang (HQ), Shanghai Jinqiao, Shanghai Lingang (API pilot), Jiangsu Qidong (biologics CDMO), Sichuan Chengdu, and Boston — plus offices in Copenhagen, the UK, and partners worldwide.
How does ChemPartner protect client IP?
Royalty-free proprietary libraries, strict project-team firewalls, bilingual SOPs, and a QMS compliant with cGMP, ICH, NMPA, FDA, and EMA.
Ready to advance your next modality?
Whether you’re optimizing a small molecule lead, building a CMC package toward IND, designing a next-generation ADC, or characterizing a cell therapy candidate, ChemPartner’s integrated platform is built to move with you.
